Promising Results from Leap Therapeutics’ Clinical Studies
Leap Therapeutics, Inc. (NASDAQ: LPTX), dedicated to the development of targeted and immuno-oncology therapeutics, has recently released encouraging initial data from two pivotal studies: Part B of the DeFianCe study and Part C of the DisTinGuish study. Their focus lies in treating advanced colorectal cancer (CRC) and gastric cancer with their innovative product, sirexatamab (DKN-01), which is combined with established therapies like bevacizumab and chemotherapy.
Insights from the DeFianCe Study
The DeFianCe study has shown an impressive objective response rate (ORR) of 35% in patients receiving sirexatamab plus bevacizumab and chemotherapy in the second-line setting for CRC, standing out against a 23% ORR in the control group. This notable difference reflects the potential benefits of introducing sirexatamab into CRC treatment protocols.
Correlation of DKK1 Levels with Efficacy
Further investigations revealed that DKK1 levels correlate strongly with clinical responses, suggesting that patients with higher DKK1 might benefit significantly from the treatment. This correlation emphasizes the need for biomarker-driven approaches in the treatment of CRC.
Planning for Future Trials
Leap Therapeutics is preparing to launch a registrational Phase 3 clinical trial that will focus on second-line CRC patients, who currently have limited treatment options. The trial aims to explore the efficacy of sirexatamab in various patient populations characterized by biomarker expression such as DKK1.
Results from the DisTinGuish Study
In the DisTinGuish study, which focuses on gastric cancer, initial data indicate some level of activity in specific biomarker populations. However, the lack of a strong signal on primary endpoints has led Leap to decide against advancing to Phase 3 studies in this indication for now.
The Importance of Patient Stratification
Despite the unmet needs in treating gastric cancer, this study highlighted the necessity for further exploration in biomarker-rich environments. Leap will consider partnerships to facilitate the advancement of sirexatamab alongside PD-1 antibodies for gastric cancer and potentially other cancer types where DKK1 expression is high.
Next Steps and Future Opportunities
Leap Therapeutics is excited about the preliminary data stemming from the DeFianCe study, anticipating future findings that could reinforce the utility of sirexatamab as crucial therapy in colorectal cancer. The company plans to continue its work with an eye toward addressing the unmet needs in this patient population.
Corporate Commitment to Innovation
With ongoing efforts directed toward enhancing treatment options for patients with heterogeneous responses to existing therapies, Leap is poised to make a significant impact in cancer treatment. Their commitment is evident in their strategic planning for clinical trials that prioritize patient safety and efficacy.
Frequently Asked Questions
What are the key findings from the DeFianCe study?
The DeFianCe study indicated a 35% objective response rate (ORR) for the combination of sirexatamab with bevacizumab and chemotherapy in second-line colorectal cancer patients.
What does the correlation of DKK1 levels mean for treatment efficacy?
Higher DKK1 levels have shown a strong correlation with better clinical responses, highlighting the potential for individualized treatment based on biomarker levels.
Is Leap Therapeutics planning any new clinical trials?
Yes, Leap is preparing to initiate a registrational Phase 3 trial focusing on second-line colorectal cancer patients following favorable data from prior studies.
What were the results of the DisTinGuish study?
The DisTinGuish study demonstrated activity in specific biomarker populations for gastric cancer but lacked sufficient positive signals to advance to Phase 3 trials.
How is Leap Therapeutics addressing the need for new cancer treatments?
Leap Therapeutics is committed to developing innovative therapies and is exploring strategic partnerships to enhance the treatment landscape for cancer, particularly in areas where there are significant unmet needs.
